Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Karuna Therapeutics, Inc.    KRTX

KARUNA THERAPEUTICS, INC.

(KRTX)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Karuna Therapeutics : Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/17/2019 | 04:01pm EST

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced it will hold a webcast and conference call on Monday, November 18, 2019 at 8:30 a.m. EST to provide results from its Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.

The dial-in numbers are 1-855-548-1216 for domestic callers and 1-409-216-6318 for international callers. The conference ID number for the live call will be 9498519. A live webcast of the conference call will also be available on the investor relations page of the Karuna Therapeutics corporate website at www.karunatx.com. After the live webcast, the event will remain archived on the Karuna Therapeutics website for three months.

About Karuna

Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with central nervous system (CNS) disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KARUNA THERAPEUTICS, INC.
12/02KARUNA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/26KARUNA THERAPEUTICS : to Present at the Piper Jaffray 31st Annual Healthcare Con..
BU
11/21KARUNA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
11/20KARUNA THERAPEUTICS : Announces Pricing of $250 Million Public Offering of Commo..
BU
11/19LONDON STOCK EXCHANGE : FTSE up for third day on China stimulus hopes, Halma jum..
RE
11/18KARUNA THERAPEUTICS : Announces Proposed Public Offering of Common Stock
BU
11/18KARUNA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
11/18KARUNA THERAPEUTICS : Announces KarXT Met Primary Endpoint in Phase 2 Clinical T..
BU
11/17KARUNA THERAPEUTICS : Schedules Webcast and Conference Call to Announce Results ..
BU
11/07KARUNA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -47,2 M
Net income 2019 -49,6 M
Finance 2019 228 M
Yield 2019 -
P/E ratio 2019 -28,8x
P/E ratio 2020 -24,8x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 1 759 M
Chart KARUNA THERAPEUTICS, INC.
Duration : Period :
Karuna Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARUNA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 103,25  $
Last Close Price 67,63  $
Spread / Highest target 98,1%
Spread / Average Target 52,7%
Spread / Lowest Target -18,7%
EPS Revisions
Sector and Competitors
1st jan.Capitalization (M$)
KARUNA THERAPEUTICS, INC.0.00%1 759
GILEAD SCIENCES7.24%84 866
VERTEX PHARMACEUTICALS34.72%57 409
REGENERON PHARMACEUTICALS-0.33%40 697
WUXI APPTEC CO., LTD.74.02%21 510
GENMAB51.29%15 541